Journal of Clinical and Translational Hepatology

Journal of Clinical and Translational Hepatology

Friday, 05 / 14 / 2021

Articles

Abstract

EDITORIAL

Very-early-stage Hepatocellular Carcinoma, Are We at Long Last on Route for Achieving Better Patient Outcomes?

Paulina Vidal-Cevallos and Norberto Chavez-Tapia*

Obesity and Digestive Disease Unit, Medica Sur Clinic and Foundation, Mexico City, Mexico
*Correspondence to: Norberto Chavez-Tapia, Obesity and Digestive Disease Unit, Medica Sur Clinic and Foundation, Puente de Piedra 150, col. Toriello Guerra, C.P., Mexico City 14050, Mexico. ORCID: https://orcid.org/0000-0002-7451-3306 .Tel: +52-55-5424-6850, E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Journal of Clinical and Translational Hepatology 2021;9(2):141-142 DOI: 10.14218/JCTH.2021.00137
Received: April 12, 2021 AcceptedApril 16, 2021 Published onlineApril 23, 2021

 

Hepatocellular carcinoma (HCC) represents ∼90% of the primary liver cancer cases, and 90% of HCC cases occur in patients with chronic liver disease.1 It also represents the sixth most common cancer (4.7%) and the third leading cause of cancer-related death globally (8.3%).2 More troubling, the global incidence and mortality rates have been increasing since 1990.3 In the United States, the highest average annual percentage change (known as AAPC) reported between 2000 and 2012 involved individuals between 55 and 59 years of age (AAPC: 8.9%; 95% confidence interval: 7.1–10.7%).4

 

The current European Association for the Study of the Liver (commonly known as EASL) guidelines advise treatment assignment according to tumor stages following the Barcelona Clinic Liver Cancer (BCLC) staging system.5 The concept of very-early or stage 0 classification was not introduced until the 2003 BCLC modification.6 Surgical resection or image-guided ablation are the first-line therapies recommended in these set of patients.5 The reported overall survival (OS) at 5 years after surgical resection is 71.1%, with a 5-year recurrence rate of 43.3%.7 In patients excluded from surgery with Child class A, the reported 5-year survival rate is 61% and 5-year recurrence rate is 81%.8

 

Journal of Clinical and Translational Hepatology 2021 vol. 9, 139-140  [ Html  ] [ PDF Full-text ]

© 2021 Authors. This is an Open Access article distributed under the terms of the  Creative Commons Attribution-Noncommercial 4.0 License(CC BY-NC 4.0), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

 logo

You are here: Home